This volume has spent seventeen chapters on how to treat the kidney. The last asks a different question: should we, and to what end? For some patients with severe AKI, the full apparatus of dialysis restores a life they value; for others, it only prolongs a dying they would not have chosen. Telling these apart is not a technical skill but a human one — honest prognosis, a genuine understanding of what the patient wants, and the humility to offer conservative care as the active, dignified treatment it can be. The chapter closes the volume on the whole patient.
Conservative kidney management is a treatment, not a default
The first idea to fix is that not dialysing is not the same as not treating. Conservative kidney management is an active, planned approach to kidney failure that withholds dialysis while doing everything else: controlling uraemic and fluid symptoms, preserving residual kidney function, treating reversible contributors, and supporting the patient and family psychologically, spiritually, and practically, with advance care planning woven through. It is a treatment choice with its own work and its own skill, and it must be offered as such — never presented as 'there is nothing more we can do.' For the right patient, it is not a lesser path but a different and often better one.
When conservative management serves the patient
The patient for whom conservative management may serve best is the frail, multi-morbid, often elderly person whose AKI sits within a larger decline, and who values quality and place of life over its mere extension. The evidence, largely observational but consistent, is that in such patients conservative management can deliver a quality of life comparable to dialysis and, in the very frail and elderly, a similar survival — with fewer hospital days, less of life spent attached to a machine, and a death more often in the preferred place. Dialysis in this group buys less time than its machinery implies and exacts a real cost in burden and dislocation. None of this argues against dialysis for the patient it serves; it argues for honestly comparing the two against what the patient actually wants.
Honest prognosis is the foundation
Every good decision here rests on a prognosis stated plainly. Severe AKI requiring dialysis carries a high short-term mortality, and that risk concentrates in the frail, the multi-organ-failure patient, and the very elderly — the same patients for whom dialysis may prolong dying rather than restore living. Prognostication is aided by frailty assessment and by the disarmingly useful surprise question: would you be surprised if this patient died in the next six to twelve months? A 'no' should prompt the goals-of-care conversation. The duty is not to predict with false precision but to be honest about uncertainty and trajectory, because a decision built on an over-optimistic prognosis is not truly shared — it is misled.
The shared-decision framework
Shared decision-making is a discipline with steps, not a single conversation. First, establish and communicate the prognosis honestly. Second, elicit the patient's values and goals — what they understand of their illness, what they hope for and fear, whether they prioritise longevity, function, comfort, or being at home. Third, present the options without bias: dialysis with its realistic burdens and benefits, conservative kidney management as an active alternative, and the time-limited trial as a way through uncertainty, using decision aids where they help. Fourth, deliberate together, respecting the patient's capacity, the role of surrogates and advance directives where capacity is lacking, and the family's place as the patient wishes. Fifth, document the decision and its reasoning, and revisit it, because goals change as illness evolves. Done well, this produces a decision the patient owns rather than one imposed on them.
The time-limited trial, withholding, and withdrawing
Two further tools deserve clarity. The time-limited trial, introduced in the dialysis chapter, starts dialysis with explicit goals and a defined review date, agreeing in advance what improvement would justify continuing and what would justify stopping — a way to act under uncertainty without an open-ended commitment, provided the review is genuine and not a formality that always continues. And the ethical bedrock: withholding and withdrawing dialysis are morally and legally equivalent. The fear that starting dialysis cannot be undone is mistaken and harmful, because it makes clinicians reluctant to offer a trial; if dialysis is started and proves not to meet the patient's goals, it can and should be stopped. Withdrawal is appropriate when the burdens outweigh the benefits, when it no longer serves the agreed goals, or when a patient with capacity requests it. After withdrawal, care turns wholly to comfort, and death usually follows over days to a few weeks, predominantly from uraemia — a course that can be made peaceful.
Conservative and comfort care: the symptoms
Choosing conservative or comfort-focused care commits the team to manage symptoms actively. Uraemia brings nausea, pruritus, restless legs, and a heavy fatigue, each of which has specific treatments. Fluid overload is eased with diuretics while they work and with fluid restriction. Pain is treated with opioids chosen for renal safety — avoiding morphine, whose metabolites accumulate, in favour of agents that do not, dosed cautiously as Chapter 17 described. Nausea, breathlessness, and the symptoms of the final days are anticipated and treated. Palliative care is a partner from the point of decision, not a service called only at the very end, and conservative management delivered well is busy, attentive care — the opposite of neglect.
Capacity, surrogates, culture, and not abandoning the patient
The decision must be made with the right person and in a way that honours who the patient is. Where the patient has capacity, their informed choice governs. Where it is lacking, decisions follow advance directives where they exist, then a surrogate exercising substituted judgment — what this patient would have wanted — and, failing that, their best interests. Cultural and religious values are central, not peripheral: patients and families bring deeply held beliefs about life, death, suffering, and the involvement of family in decisions, and good care respects and works within them rather than around them, involving family to the extent the patient wishes. Through all of it runs one non-negotiable commitment: whatever the patient chooses, they are not abandoned. 'We will care for you, whatever you decide' is the sentence that holds the whole framework together, and it is the note on which a volume about a frightening, often fatal syndrome should end — on the person, not the kidney.
Where the evidence is firm, and where judgement governs
As elsewhere, it helps to mark what is settled. That withholding and withdrawing are ethically equivalent is firm ethical and legal consensus. That conservative management can match dialysis on quality of life, and survival in the very frail, is supported by consistent observational data, though not by randomised trials, which are hard to do here. The prognostic tools are useful but imprecise. And the decisions themselves — whether to dialyse, when to stop, where to be cared for — are not the kind that evidence can settle, because they turn on values that are the patient's to weigh. The clinician's expertise is to bring honest prognosis and clear options to a conversation whose conclusion belongs to the patient. That is the proper close to a clinical volume: the science fully deployed, and then placed in the service of a human choice.
